{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:34:10Z","timestamp":1790393650119,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma (NHL) whose clinical course is largely shaped by molecular and biological features. Among the most impactful prognostic markers, TP53 mutations have emerged as critical determinants of treatment resistance since their first identification in MCL in 1996. Regardless of the detection method, TP53 mutations have been consistently associated with primary refractoriness to chemoimmunotherapy and significantly reduced overall survival. In this perspective, we explored recent advances in applying integrated-omics approaches to assess TP53 status. Despite its prognostic value, routine testing for TP53 at diagnosis remains uncommon, hindered by the lack of standardized protocols and costs for Next-Generation Sequencing (NGS), and the suboptimal reliability of immunohistochemistry (IHC) as a surrogate. This gap between research evidence and clinical practice represents a critical barrier to risk-adapted therapy. The broad implementation of standardized and accessible genomic techniques is essential to identify patients who deserve a personalized therapeutic approach. Several clinical trials have recently explored alternative chemo-free or targeted regimens specifically tailored to TP53-mutated patients (i.e., NCT03824483, NCT03567876), with promising results. This risk-adapted approach reflects a paradigm shift in MCL management, emphasizing the need for early molecular risk assessment to guide treatment decisions. In this scenario, TP53 mutations are no longer supporting actors, but a game-changer for the prognosis and treatment of patients with MCL.<\/jats:p>","DOI":"10.3390\/jcm14238480","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8480","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["TP53 Mutations in Mantle Cell Lymphoma: From Backup to Game Changer"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2742-2779","authenticated-orcid":false,"given":"Maria Elena","family":"Carazzolo","sequence":"first","affiliation":[{"name":"University Laboratory for Medical Research (LURM), Department of Medicine, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-4941","authenticated-orcid":false,"given":"Alessia","family":"Moioli","sequence":"additional","affiliation":[{"name":"Centro Ricerche Cliniche s.r.l, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-0883","authenticated-orcid":false,"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Department of Engineering for Innovation Medicine, Section of Biomedicine, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","article-title":"Molecular Pathogenesis of Mantle Cell Lymphoma","volume":"34","author":"Navarro","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/EDBK_349509","article-title":"New Directions for Mantle Cell Lymphoma in 2022","volume":"42","author":"Kumar","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106824","DOI":"10.1016\/j.leukres.2022.106824","article-title":"Mantle cell lymphoma and the evidence of an immature lymphoid component","volume":"115","author":"Hansen","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3324\/haematol.2017.184325","article-title":"A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: Results from the Fondazione Italiana Linfomi MCL-0208 trial","volume":"103","author":"Bomben","year":"2018","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clml.2018.07.282","article-title":"TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients with Mantle Cell Lymphoma","volume":"18","author":"Obr","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2011.055715","article-title":"The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index","volume":"97","author":"Koch","year":"2012","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.5858\/2000-124-1457-MIAOTC","article-title":"Multiparameter Immunohistochemical Analysis of the Cell Cycle Proteins Cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in Mantle Cell Lymphoma","volume":"124","author":"Izban","year":"2000","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjh.17023","article-title":"p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma","volume":"191","author":"Rodrigues","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.anndiagpath.2019.05.004","article-title":"TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant","volume":"41","author":"Sakhdari","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1080\/10428194.2018.1542144","article-title":"ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients","volume":"60","author":"Mareckova","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.2019002385","article-title":"Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing","volume":"136","author":"Pararajalingam","year":"2020","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"S\u00f6nmez, E.E., Hatipo\u011flu, T., Kur\u015fun, D., Hu, X., Akman, B., Yuan, H., Danyeli, A.E., Alacac\u0131o\u011flu, \u0130., \u00d6zkal, S., and Olgun, A. (2022). Whole Transcriptome Sequencing Reveals Cancer-Related, Prognostically Significant Transcripts and Tumor-Infiltrating Immunocytes in Mantle Cell Lymphoma. Cells, 11.","DOI":"10.3390\/cells11213394"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1182\/bloodadvances.2023011763","article-title":"Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma","volume":"8","author":"Silkenstedt","year":"2024","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in Context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103071","DOI":"10.1016\/j.critrevonc.2020.103071","article-title":"Function and regulation of lipid signaling in lymphomagenesis: A novel target in cancer research and therapy","volume":"154","author":"Guo","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1111\/bjh.17063","article-title":"A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma","volume":"191","author":"Obr","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Roszkowska, K.A., Piecuch, A., Sady, M., Gajewski, Z., and Flis, S. (2022). Gain of Function (GOF) Mutant p53 in Cancer\u2014Current Therapeutic Approaches. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113287"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood.2023022354","article-title":"High-risk MCL: Recognition and treatment","volume":"145","author":"Jain","year":"2025","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1111\/cas.14905","article-title":"CDKN1C-mediated growth inhibition by an EZH1\/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib","volume":"112","author":"Kagiyama","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gambino, S., Quaglia, F.M., Galasso, M., Cavallini, C., Chignola, R., Lovato, O., Giacobazzi, L., Caligola, S., Adamo, A., and Putta, S. (2024). B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-55728-9"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB\u2013targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9762","DOI":"10.1038\/s41467-025-64666-7","article-title":"Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma","volume":"16","author":"Sharma","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood.2023020211","article-title":"CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma","volume":"142","author":"Decombis","year":"2023","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Granau, A.M., Andersen, P.A., Jakobsen, T., Taouxi, K., Dalila, N., Mogensen, J.B., Kristensen, L.S., Gr\u00f8nb\u00e6k, K., and Dimopoulos, K. (2023). Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma. Cancers, 15.","DOI":"10.3390\/cancers15020510"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.20.02287","article-title":"High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management","volume":"38","author":"Jain","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_29","first-page":"699","article-title":"Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma","volume":"36","author":"Stefancikova","year":"2010","journal-title":"Int. J. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Klapper","year":"2015","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.21873\/anticanres.16120","article-title":"Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis","volume":"42","author":"Yi","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e777","DOI":"10.1016\/S2352-3026(25)00252-2","article-title":"Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): A multicentre, single-arm, phase 2 study","volume":"12","author":"Visco","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: The phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in Relapsed\/Refractory Mantle Cell Lymphoma: Results from a Phase I\/II Study","volume":"43","author":"Phillips","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2024-200018","article-title":"Paper: Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I\/II Study","volume":"144","author":"Phillips","year":"2024","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00428-020-02750-7","article-title":"Reproducibility of histologic prognostic parameters for mantle cell lymphoma: Cytology, Ki67, p53 and SOX11","volume":"477","author":"Croci","year":"2020","journal-title":"Virchows Arch."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cac2.12023","article-title":"Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","article-title":"Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: An immunohistochemical and nucleotide sequencing analysis","volume":"24","author":"Yemelyanova","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cole, A.J., Dwight, T., Gill, A.J., Dickson, K.-A., Zhu, Y., Clarkson, A., Gard, G.B., Maidens, J., Valmadre, S., and Clifton-Bligh, R. (2016). Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci. Rep., 6.","DOI":"10.1038\/srep26191"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Bankhead, P., Loughrey, M.B., Fern\u00e1ndez, J.A., Dombrowski, Y., McArt, D.G., Dunne, P.D., McQuaid, S., Gray, R.T., Murray, L.J., and Coleman, H.G. (2017). QuPath: Open source software for digital pathology image analysis. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-17204-5"},{"key":"ref_50","unstructured":"(2025, July 21). HALO Quantitative Image Analysis for Pathology. Available online: https:\/\/www.leicabiosystems.com\/it-it\/digital-pathology\/analyze\/halo\/."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00277-022-04922-8","article-title":"Prognostic value and computer image analysis of p53 in mantle cell lymphoma","volume":"101","author":"Zhang","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mne.2018.10.006","article-title":"Fluorescence in situ hybridization (FISH): History, limitations and what to expect from micro-scale FISH?","volume":"1","author":"Huber","year":"2018","journal-title":"Micro Nano Eng."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e70072","DOI":"10.1002\/hon.70072","article-title":"Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target","volume":"43","author":"Ferrero","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"103200","DOI":"10.1016\/j.dnarep.2021.103200","article-title":"Significance and limitations of the use of next-generation sequencing technologies for detecting mutational signatures","volume":"107","author":"Abbasi","year":"2021","journal-title":"DNA Repair"},{"key":"ref_55","unstructured":"(2025, September 23). Advantages and Limitations of Sanger Sequencing. Genetic Education. Available online: https:\/\/geneticeducation.co.in\/advantages-and-limitations-of-sanger-sequencing\/."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1038\/s41375-024-02375-8","article-title":"Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: Results from the EU-MCL network trials","volume":"38","author":"Khouja","year":"2024","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12935-025-03789-9","article-title":"Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphoma","volume":"25","author":"Ouyang","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-020-00961-8","article-title":"Advances in the assessment of minimal residual disease in mantle cell lymphoma","volume":"13","author":"Jung","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Malarikova, D., Berkova, A., Obr, A., Blahovcova, P., Svaton, M., Forsterova, K., Kriegova, E., Prihodova, E., Pavlistova, L., and Petrackova, A. (2020). Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy. Cancers, 12.","DOI":"10.3390\/cancers12082120"},{"key":"ref_60","unstructured":"(2025, July 22). EuroClonality\u2014NDC Assay by Univ8 Genomics. Available online: https:\/\/univ8genomics.com\/euroclonality-ndc\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjh.17519","article-title":"Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: First data from the Fondazione Italiana Linfomi MCL0208 trial","volume":"194","author":"Genuardi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating Tumor DNA in Lymphoma Principles and Future Directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/blood-2024-198076","article-title":"TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial","volume":"144","author":"Moia","year":"2024","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00428-023-03676-6","article-title":"Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas","volume":"485","author":"Noordenbos","year":"2024","journal-title":"Virchows Arch."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Galimberti, S., Balducci, S., Guerrini, F., Del Re, M., and Cacciola, R. (2022). Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool. Diagnostics, 12.","DOI":"10.3390\/diagnostics12061305"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Coccaro, N., Tota, G., Anelli, L., Zagaria, A., Specchia, G., and Albano, F. (2020). Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093141"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Chen, L., Mu, W., Gu, J., Xiao, M., Huang, L., Zheng, M., Li, C., Xiao, Y., Zhou, J., and Long, X. (2021). TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy. Diagnostics, 11.","DOI":"10.3390\/diagnostics11050844"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood-2019-123812","article-title":"High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma","volume":"134","author":"Obr","year":"2019","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8480\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:25:18Z","timestamp":1765211118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":68,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14238480"],"URL":"https:\/\/doi.org\/10.3390\/jcm14238480","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]}}}